Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Titan Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ: TTNP
Industry Pharmaceuticals
Headquarters California
Number of employees
14 (Dec 2016)
Website www.titanpharm.com

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.

Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.


Investment goal date:
Dividends reinvested
Titan Pharmaceuticals, Inc. TTNP report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-03-21
--
--
Q4 2017
2018-03-16
--
--
Q3 2017
2017-11-09
--
--
Q3 2017
2017-11-09
-0.2000
0.0000
Q2 2017
2017-08-09
-0.1700
-0.1600
Q1 2017
2017-05-10
-0.1400
-0.1400
Q4 2016
2017-03-16
-0.1500
-0.1500
Q3 2016
2016-11-09
-0.1200
-0.1200
Q2 2016
2016-08-09
0.5500
0.5500
Q1 2016
2016-05-10
-0.0900
-0.0900
Q4 2015
2016-03-15
-0.1100
-0.1100
Q3 2015
2015-11-16
-0.0900
-0.0900
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Bank of New York Mellon Corp
62270
BlackRock Fund Advisors
600300
BlackRock Inc.
803369
BlackRock Institutional Trust Company, N.A.
131115
BlackRock Investment Management, LLC
71414
DIMENSIONAL FUND ADVISORS LP
59559
GEODE CAPITAL MANAGEMENT, LLC
121865
GOLDMAN SACHS GROUP INC
100933
MORGAN STANLEY
68230
NORTHERN TRUST CORP
205367
Parallax Volatility Advisers, L.P.
80000
RENAISSANCE TECHNOLOGIES LLC
236714
STATE STREET CORP
291564
STRS OHIO
107400
Vanguard Group, Inc
707743
Major Shareholders
Name Relationship
Total Shares
Holding stocks